Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces by Evyn Peters, Arash Shamloo, Rohit J. Lodhi, Gene Marcoux, Kylie Jackson, Shawn Halayka, Lloyd Balbuena

“…Cohort members were required to have a minimum of 6 weeks medicated with aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.ResultsThe multistate model predicted that schizophrenia patients accumulated 44 months in SGA monotherapy, 4 months in polypharmacy, 11 months in medication gaps and 17 days in clozapine over a 5-year period. …”
Get full text

Aripiprazole as a treatment option for delusional parasitosis: case series of 8 patients by Meltem Çınar, Pelin Kutlutürk, İrem Ekmekçi Ertek, Behçet Coşar

“…Various researches are available related to the usage of second-generation antipsychotics like risperidone, olanzapine, paliperidone, ziprasidone, quetiapine, and aripiprazole in the cases with DP. …”
Get full text

A case report and literature review of olanzapine-associated hyperglycemia with previous history of gestational diabetes by Jennifer N. Alastanos, PharmD, BCPP, BCPS, Devika Suri, PharmD, Hayato DeLellis, PharmD, Andrea Mapugay, PharmD

“…She was later discharged on ziprasidone 20 mg PO twice daily. Discussion: There have been several case reports published on olanzapine-induced hyperglycemia. …”
Get full text

Gradient Boosting Decision Tree-Based Method for Predicting Interactions Between Target Genes and Drugs by Ping Xuan, Chang Sun, Tiangang Zhang, Yilin Ye, Tonghui Shen, Yihua Dong

“…In addition, case studies on Quetiapine, Clozapine, Olanzapine, Aripiprazole, and Ziprasidone demonstrate the ability of DTIGBDT to discover potential drug–target interactions.…”
Get full text

Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis by Davies, C, Cipriani, A, Ioannidis, J, Radua, J, Stahl, D, Provenzani, U, McGuire, P, Fusar-Poli, P

“…The treatments tested were needs‐based interventions (NBI); omega‐3 + NBI; ziprasidone + NBI; olanzapine + NBI; aripiprazole + NBI; integrated psychological interventions; family therapy + NBI; D‐serine + NBI; cognitive behavioural therapy, French and Morrison protocol (CBT‐F) + NBI; CBT‐F + risperidone + NBI; and cognitive behavioural therapy, van der Gaag protocol (CBT‐V) + CBT‐F + NBI. …”

Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials by Michel Sabe, Nan Zhao, Alessio Crippa, Stefan Kaiser

“…The 95% effective doses per day for the 13 antipsychotics included and 3 long acting were mostly different for negative and positive symptoms: amisulpride (481 mg, 690.6 mg); aripiprazole (11.9 mg, 11 mg); asenapine (7.61 mg, 5.66 mg); brexpiprazole (2.1 mg, 4 mg); cariprazine (4 mg, 6.51 mg); haloperidol (6.34 mg, 7.36 mg); lurasidone (58.2 mg, 86.3 mg); olanzapine (15.5 mg, 9.52 mg); olanzapine long-acting injection (15.7 mg, 13.5 mg); paliperidone (7.2 mg, 7 mg); paliperidone long-acting injection (7.5 mg, 5.9 mg); quetiapine instant-release (264.2 mg, 316.5 mg); quetiapine extended-release (774 mg, 707.2 mg); risperidone (7.5 mg, 7.7 mg); risperidone long-acting injection (5.13 mg, 6.7 mg); sertindole (13.5 mg, 16.3 mg); and ziprasidone (71.6 mg, 152.6 mg). The shape of the dose-response curves varied across different drugs with most drugs showing a plateau at higher doses. …”
Get full text

Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review by Alice Caldiroli, Enrico Capuzzi, Ilaria Tagliabue, Martina Capellazzi, Matteo Marcatili, Francesco Mucci, Fabrizia Colmegna, Massimo Clerici, Massimiliano Buoli, Antonios Dakanalis

“…Moreover, olanzapine, quetiapine, cariprazine, risperidone, and ziprasidone showed positive results but to a lesser extent. …”
Get full text

Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis by David D. Kim, Alasdair M. Barr, Lulu Lian, Jessica W. Y. Yuen, Diane Fredrikson, William G. Honer, Allen E. Thornton, Ric M. Procyshyn

“…Specifically, aripiprazole was more favorable than paliperidone for triglyceride levels and more favorable than risperidone and olanzapine, but less favorable than ziprasidone, for weight gain. In addition, aripiprazole was less favorable for akathisia compared with second-generation D2R antagonists, in particular olanzapine and quetiapine, and less favorable for discontinuation due to inefficacy than risperidone. …”
Get full text

Assessment of hospitalizations in schizophrenia patients treated with paliperidone 1-monthly (PP1M), paliperidone 3-monthly (PP3M), aripiprazole once-monthly (AOM) and other oral a... by L. Gutiérrez Rojas, S. Sánchez Alonso, M. García Dorado, P. Lopez

“…Methods All adults (≥18 years) with schizophrenia who were initiated on PP1M, PP3M, AOM, or OAP treatment (chlorpromazine,levomepromazine,fluphenazine,haloperidol,ziprasidone,zuclopenthixol,olanzapine,quetiapine,asenapine,amisulpride, risperidone,aripiprazole,paliperidone) between 2017 and 2018 were identified in IQVIA’s database(1.8M of inhabitants from 4 Spanish areas). …”
Get full text

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations by Yifei Liu, Mark E. Patterson, Suman Sahil, Steven C. Stoner

“…Background: Long-acting injectable (LAI) antipsychotics (APs) each have an oral equivalent formulation, while aripiprazole, olanzapine, and ziprasidone each also have a short-acting injectable (SAI) equivalent formulation. …”
Get full text

Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: A network meta-analysis by Davies, C, Radua, J, Cipriani, A, Stahl, D, Provenzani, U, McGuire, P, Fusar-Poli, P

“…In the NMA for efficacy, ziprasidone + Needs-Based Intervention (NBI) was found to be superior to NBI (SMD = -1.10, 95% CI -2.04 to -0.15), Cognitive Behavioral Therapy-French and Morrison protocol (CBT-F) + NBI (SMD = -1.03, 95% CI -2.05 to -0.01), and risperidone + CBT-F + NBI (SMD = -1.18, 95% CI -2.29 to -0.07) at 6 months. …”

Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences by Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, Anna Pintaudi, Marco Baldini, Stefano Aringhieri, Irene Fasciani, Paolo Annibale, Roberto Maggio, Marco Scarselli

“…The new AAPs such as ziprasidone, lurasidone and the partial agonist aripiprazole seem more tolerable on the metabolic profile. …”
Get full text

Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia by Andre F Carvalho, Ping-Tao Tseng, Trevor Thompson, Chih-Wei Hsu, Chia-Ling Yu, Chih-Sung Liang, Tzu-Cheng Tsai, Tien-Wei Hsu

“…The dose equivalents to olanzapine (with SD) were 0.68 (0.23) for haloperidol, 0.32 (0.07) for risperidone, 0.60 (0.11) for paliperidone, 8.00 (1.41) for ziprasidone, 41.46 (5.98) for quetiapine, 1.65 (0.32) for aripiprazole, 1.23 (0.20) for asenapine, 0.53 (0.14) for cariprazine and 0.22 (0.03) for brexpiprazole. …”
Get full text

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis by Leucht, S, Örey, D, Richter, F, Samara, M, Kissling, W, Stapf, M, Lässig, B, Cipriani, A, Barbui, C, Spineli, L, Mavridis, D, Salanti, G, Engel, R, Geddes, J, Davis, J

“…The standardised mean differences with 95% credible intervals were: clozapine 0.88, 0.73-1.03; amisulpride 0.66, 0.53-0.78; olanzapine 0.59, 0.53-0.65; risperidone 0.56, 0.50-0.63; paliperidone 0.50, 0.39-0.60; zotepine 0.49, 0.31-0.66; haloperidol 0.45, 0.39-0.51; quetiapine 0.44, 0.35-0.52; aripiprazole 0.43, 0.34-0.52; sertindole 0.39, 0.26-0.52; ziprasidone 0.39, 0.30-0.49; chlorpromazine 0.38, 0.23-0.54; asenapine 0.38, 0.25-0.51; lurasidone 0.33, 0.21-0.45; and iloperidone 0.33, 0.22-0.43. …”

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. by Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, Samara, M, Barbui, C, Engel, R, Geddes, J, Kissling, W, Stapf, M, Lässig, B, Salanti, G, Davis, J

“…The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. …”

New role of platelets in schizophrenia: predicting drug response by Tao Li, Wei Wei, Qiang Wang, Yamin Zhang, Wei Deng, Rui Xue, Wanjun Guo, Xiaojing Li, Hua Yu, Yanghao Zheng, Peiyan Ni, Sugai Liang, Xueyu Qi, Xueli Yu, Liansheng Zhao

“…Repeated measures analysis of variance was used to examine the effect of antipsychotics on PLTc changes, while structural equation modelling was used to assess the predictive value of PLTc on PANSS changes.Results PLTc significantly increased in patients treated with aripiprazole (F=6.00, p=0.003), ziprasidone (F=7.10, p<0.001) and haloperidol (F=3.59, p=0.029). …”
Get full text

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis by Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, Krause, M, Samara, M, Peter, N, Arndt, T, Bäckers, L, Rothe, P, Cipriani, A, Davis, J, Salanti, G, Leucht, S

“…Mean differences compared to placebo for weight gain (28 317 participants) ranged from −0·16 kg (−0·73 to 0·40; ziprasidone) to 3·21 kg (2·10 to 4·31; zotepine), for prolactin elevation (21 569 participants) from −77·05 ng/mL (−120·23 to −33·54; clozapine) to 48·51 ng/mL (43·52 to 53·51; paliperidone) and for QTc prolongation (15 467 participants) from −2·21 ms (−4·54 to 0·15; lurasidone) to 23·90 ms (20·56 to 27·33; sertindole). …”

Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis by Liang-Kun Guo, Yi Su, Yu-Ya-Nan Zhang, Hao Yu, Zhe Lu, Wen-Qiang Li, Yong-Feng Yang, Xiao Xiao, Hao Yan, Tian-Lan Lu, Jun Li, Yun-Dan Liao, Zhe-Wei Kang, Li-Fang Wang, Yue Li, Ming Li, Bing Liu, Hai-Liang Huang, Lu-Xian Lv, Yin Yao, Yun-Long Tan, Gerome Breen, Ian Everall, Hong-Xing Wang, Zhuo Huang, Dai Zhang, Wei-Hua Yue

“…The discovery cohort was recruited from the CAPOC trial (n = 2307) involved 6 weeks of treatment and equally randomized the participants to the Olanzapine, Risperidone, Quetiapine, Aripiprazole, Ziprasidone, and Haloperidol/Perphenazine (subsequently equally assigned to one or the other) groups. …”
Get full text

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial by Minhan Dai, Yulu Wu, Yiguo Tang, Weihua Yue, Hao Yan, Yamin Zhang, Liwen Tan, Wei Deng, Qi Chen, Guigang Yang, Tianlan Lu, Lifang Wang, Fude Yang, Fuquan Zhang, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Hongyan Zhang, Xin Ma, Lingjiang Li, Chuanyue Wang, Xiaohong Ma, Dai Zhang, Hao Yu, Liansheng Zhao, Hongyan Ren, Yingcheng Wang, Xun Hu, Guangya Zhang, Xiaodong Du, Qiang Wang, Tao Li

“…There was no differential contribution of high- and low trajectories to different drugs (χ2 = 12.52, P = 0.051); olanzapine and risperidone, which had a larger proportion in the >50% reduction at week 6, performed better than aripiprazole, quetiapine, ziprasidone and perphenazine. Conclusions The trajectory analysis of treatment response to schizophrenia revealed two distinct trajectories. …”
Get full text